Matches in Nanopublications for { ?s ?p "DDI between Ketoconazole and Tolbutamide - Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed."@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB01026_DB01124 title "DDI between Ketoconazole and Tolbutamide - Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed." assertion.